Neurological disorders collaboration crosses three countries

China, Canada and the USA are all represented in a collaboration to jointly develop a therapy for neurologic disorders by harnessing the natural power of the immune system.

Chinese firms I-Mab Biopharma, a biotech focused on immuno-oncology and autoimmune diseases, and CNS company Jiangsu Nhwa Pharmaceutical, have entered into a collaborative research agreement with both scientists and clinicians at the USA’s Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital, and Biodextris, a Montreal-based biologics CDMO.

"The development of a nasal immune modulator that has been used in vaccines is a unique approach to treating certain neurologic disease and has the potential to have a major impact"The parties will combine their resources and expertise in basic science, translational research, clinical development, manufacturing and commercialization, to accelerate the translation of innovative immunotherapy into the clinic for the most challenging diseases with the highest unmet medical needs.